Over 100 million HPV Tests and counting
Over 100 million women screened for HPV with QIAGEN solutions. We are proud to be a partner in fighting cervical cancer with our HPV testing solutions. Learn about our commitment to screening 100 million more. We are committed to reaching every woman with our comprehensive portfolio, which includes tests for diverse menu options, risk stratification, and limited resource settings.
Continuing a legacy that began with the digene HC2 Test, QIAGEN now brings you QIAscreen, QIAsure and the careHPV Test
The latest addition to the most comprehensive HPV portfolio: QIAscreen
QIAscreen is an in vitro real-time PCR-based assay for the qualitative detection of human papillomavirus (HPV) DNA of 15 (likely) (1) high-risk HPV genotypes. QIAscreen combines QIAGEN’s leading sample prep excellence from QIAsymphony and Rotor Gene with our expertise in HPV diagnostics.
Watch the video to learn more about the new QIAscreen test.
Not all HPV-positives are the same. Be confident in the difference with QIAsure.
With QIAsure, clinicians can stratify the risk of high risk-HPV positive patients. This innovative test objectively detects the presence of biomarkers associated with cervical precancer and cancer in the PCR lab, using the same sample from an HPV or liquid-based cytology test. QIAsure provides peace of mind for patients to live their lives with confidence about their reproductive health.
Adaptable and affordable high-risk HPV test
With proper training, the careHPV Test is run by healthcare workers with no formal laboratory skills.
The careHPV Test runs on electricity or a battery with an inverter, making it portable and adaptable.
The temperature range is flexible, from 15°C to 40°C.
Additional careHPV Test benefits include:
- Detection of 14 high-risk HPV types
- Convenient test results in 2.5 hours (excluding sample prep) for possible same-day follow up
- High clinical sensitivity and specificity
The careHPV test is on the WHO’s list of prequalified in vitro diagnostics, meaning it is suitable for cervical cancer screening in resource-limited settings and eligible for inclusion in UN procurement tenders. This status significantly broadens access to HPV DNA testing to areas of the world with a high burden of cervical cancer.
The digene HC2 HPV Test is the most sensitive HPV test on the market
When it comes to cervical cancer screening, sensitivity is the key. Early detection allows you to make more thorough and informed patient management decisions. The digene HC2 HPV Test is:
- Internationally recognized as the gold standard
- The most validated HPV test on the market
- The only HPV assay that provides complete genome coverage
Additionally, the digene HC2 HPV Test:
- Has sold 100,000,000+ tests worldwide
- Has 2000+ publications
- Is used in 40+ countries
QIAGEN is a leader in cervical cancer screening. See how our customers are using QIAGEN HPV solutions.
See how the digene HC2 HPV test is the gold standard in Ivana Hojsikova’s work.
Jose Eduardo Levi uses digene HC2 and believes HPV testing should be available for all women worldwide.
In Russia, digene HC2’s high sensitivity is why this is their test of choice.
Murat Gueltekin describes the impact of the digene HC2 test on Turkey’s cervical cancer screening program.
Share your HPV story and get an exclusive QIAGEN T-shirt while supplies last.* Your story may get featured here!
Share your HPV storyGet the latest statistics on cervical cancer
Download the infographicThe development of cervical cancer screening
The Papanicolaou (Pap) Test
- Introduced by George Papanicolaou in 1949
- A significant step that had a tremendous impact in developed countries
- Limitations for large-scale implementation in LMIC
HPV as cause of cervical cancer
- Discovered by Professor Harald zur Hausen in the early 1980’s
- HPV-16 and HPV-18 DNA was found in cervical tumor samples
- Discovery recognized for a Nobel Prize in Medicine in 2008
The digene HC2 HPV Test
- First HPV DNA test approved by the FDA
- Provided clinicians a new tool for cervical cancer screening
- Over 100 million tests performed
The QIAsure and QIAscreen Tests
- New HPV tests obtained CE approval from 2016–2018
- QIAsure stratifies risk for HPV-positive patients
- QIAscreen is a real-time PCR solution
The careHPV Test, QIAsure Methylation Test, and QIAscreen HPV PCR Tests are not available in the United States.
*Testimonials will be reviewed by QIAGEN and uploaded upon completion of the electronic release form by the customer. An additional release form is required if the customer uses their employer’s name in the testimonial. QIAGEN reserves the right to upload testimonials to the website. T-shirts are available while supplies last and are limited to one T-shirt per person. Offer not available in all countries. Void where prohibited and may be subjected to reporting as dictated by the US Sunshine Act laws.
References
1. International Agency for Research on Cancer. (2009). A review of human carcinogens. Part B: Biological Agents. Monographs 100B.